You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
One-click Automated 3D Treatment Planning for Radiopharmaceutical Therapy
SBC: VOXIMETRY INC Topic: 102PROJECT SUMMARY/ABSTRACT The Radiopharmaceutical Therapy (RPT) market is projected to surpass the Technitium-99m market by 2025, with an emphasis on metastatic prostate cancer, neuroendocrine tumors, and lymphoma. Driven by well- tolerated treatments and fewer side-effects, experts have estimated 150 new theranostic centers will be needed in the U.S. to deliver an estimated 50,000–200,000 treatm ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
SBC: SIGNABLOK, INC. Topic: NHLBIProject Summary/Abstract Every year, 150,000 Americans are affected by Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition that may complicate severe pneumonia (including influenza and COVID-19), trauma, sepsis, cancer, and many other conditions. The mortality of ARDS is 27%, 32%, and 45% for mild, moderate, and severe disease, respectively. The survival rate for COVID-19 pa ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Manganese Based MRI Contrast Agent
SBC: Reveal Pharmaceuticals, Inc. Topic: NCIGadolinium (Gd)-based MRI contrast agents (GBCAs) are used in clinical magnetic resonance imaging (MRI) for cancer detection and staging, particularly of primary and metastatic brain cancers. However, there are concerns about the potential long-term toxicity of GBCAs. GBCAs cause nephrogenic systemic fibrosis (NSF), a devastating disorder that affects patients with kidney disease. FDA imposed a †...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Machine Learning Based Differential Mobility Spectrometry Library Development
SBC: VOX BIOMEDICAL LLC Topic: 400Project Summary The goal of the project proposed is to develop a gas chromatography and differential mobility spectrometry (GC/DMS) molecular identification library for volatile organic compounds (VOCs) using a deep neural network approach. Vox Biomedical scientists will test the hypothesis that a novel, multi-task neural network architecture can predict characteristics of an previously unseen ana ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials
SBC: CANGET BIOTEKPHARMA, LLC Topic: 102Abstract/Summary The goals of this SBIR Phase I grant are: (1) to use the clinically compatible FL118 product to perform the non- good laboratory practice (GLP) and GLP toxicology (TOX) and toxicokinetics (TK) studies; and (2) to author and file the FL118 Investigational New Drug (IND) application with the FDA for first-in-human FL118 phase 1 clinical trials in patients with advanced pancreatic du ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A conversational agent to support remote care for individuals with substance use disorder
SBC: DIMAGI, INC. Topic: NIDAPROJECT SUMMARY Substance use disorder (SUD) is a significant public health challenge, and it has been estimated that its effects on healthcare, work productivity, and criminal justice costs the US over $600 billion annually. Engagement with the clinical care team is critical to an individual’s path to SUD recovery; however, limited capacity of and access to addiction treatment providers and tra ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Bloomer Augmented Garment Platform-Barrier Removal for women in cArdiac rehab (BRA)
SBC: BLOOMER HEALTH TECH., INC. Topic: NHLBIPROJECT SUMMARY Bloomer Tech is advancing development of the Bloomer Augmented Garment Platform, a wearable bra with embedded sensors to address cardiovascular healthcare disparities in women. Cardiovascular disease is the leading cause of death in women, resulting in nearly 315,000 deaths in the U.S. in 2020, where women generally experience worse outcomes than men including increased disability, ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of brain-penetrant COMT inhibitors for the treatment of depressive disorders
SBC: PSY THERAPEUTICS, INC. Topic: 101PROJECT SUMMARYMajor depressive disorder (MDD) is a serious, debilitating, and often recurring disorder with a substantial lifetime risk and a high societal cost. Depressed patients frequently display a variety of co-morbid symptoms, including depressed moods, loss of motivation and/or reductions in the ability to experience pleasure (anhedonia), loss of interest and energy, combined with psycholo ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
USE OF DYRK1A/B KINASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES
SBC: Avanti Biosciences Inc Topic: 300PROJECT SUMMARYNonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. One-fourth of the adult population suffers from NAFLD worldwide. Nonalcoholic steatohepatitis (NASH), the aggressive form of NAFLD, can progress to cirrhosis and hepatocellular cancer (HCC) and is rapidly becoming the leading cause of end-stage liver disease and liver transplantation. Liver fibrosi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
High-throughput 3D mapping of large mammalian brains via integration of precision tissue sectioning and light sheet imaging
SBC: LifeCanvas Technologies Inc. Topic: 101Whole-brain mapping at the cellular and subcellular levels is crucial to systematically understand brain functions and disorders. Recent developments in tissue transformation techniques, such as CLARITY, SHIELD, MAP, ExM, CUBIC, and DISCO-based methods, have made significant progress towards whole-organ molecular labeling and microscopic imaging by rendering intact tissue chemically permeable and ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health